Table 3 Potential biomarkers for patient selection for immunotherapy in breast cancer
From: Checkpoint blockade in the treatment of breast cancer: current status and future directions
Biomarker | Method of assessment | Evidence |
|---|---|---|
TILs | H&E slides | Pembrolizumab monotherapy in metastatic TNBC: Median (IQR) TIL level in responders vs. non-responders was 10% (7.5–25%) vs. 5% (1–10%) in cohort A (previously treated, any PD-L1 expression) and 50% (5–70%) vs. 15% (5–37.5%) in cohort B (previously untreated, PD-L1 positive)64 |
PDL1 | IHC (VENTANA PD-L1 (SP142) Assay) | Atezolizumab in combination with nab-paclitaxel in metastatic TNBC: ORR IC0 = 57.1% (95% CI: 18.4, 90.1) ; ORR IC1/2/3 = 77.8% (95% CI: 40.0, 97.2);60 IC0 = <1% of immune cells or tumour cells staining positive for PD-L1 ; IC1 = ≥1% and <5% of immune cells or tumour cells staining positive for PD-L1 ; IC2 = ≥5% and <10% of immune cells or tumour cells staining positive for PD-L1 ; IC3 = ≥10% of immune cells or tumour cells staining positive for PD-L1 |
